ClinicalTrials.gg
CompletedNCT00171808deFENDUpdated Nov 18, 2016

Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer

A Phase 2 interventional study of Letrozole in Endometrial Cancer, sponsored by Novartis Pharmaceuticals. Completed at 15 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing letrozole in Endometrial Neoplasms — 5 open to participants now, 9 under way, 3 of them phase 3. Letrozole · Endometrial Neoplasms.

Enrollment
16th of 17
26 · median 53
Started
2005
the only one that year
Phase 2
12 of 17
2 open now
Registered
2nd of 17
by date
Lead sponsor
2 of 17
Novartis Pharmaceuticals

Among the 17 studies testing letrozole in Endometrial Neoplasms, this one is the 16th largest by enrollment, is the only one that started in 2005, is one of 12 in phase 2, and was the 2nd registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

5 of the 17 studies testing letrozole in Endometrial Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About letrozole

Letrozole: first FDA approval 1997 (FEMARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing letrozole in Endometrial Neoplasms, or all of them as a file.
02

Study summary

In Western industrialized countries, endometrial cancer is the most common malignancy of the female reproductive tract.

The general therapy options are surgery, radiotherapy, chemotherapy and endocrine therapy. This trial will investigate the efficacy and safety of letrozole in the treatment of advanced or recurrent hormone receptor-positive endometrial cancer .

03

Conditions studied

  • Endometrial Cancer

Keywords

  • Endometrial Cancer
  • Aromatase inhibitor
  • Advanced or recurrent
  • hormone receptor positive
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Age > 18 years
  • Presence of proven adenocarcinoma or adenosquamous carcinoma of the endometrium
  • Presence of advanced or recurrent endometrial cancer, FIGO stage I-IV, incurable with surgery and/or radiation therapy
  • Documented ER and/or PgR positive endometrial cancer. Hormone receptor positivity is defined according to routine practice at each participating laboratory.
  • Patient must be defined as

    • Age ≥55 years.
    • Age \<55 but no spontaneous menses for at least 1 year.
    • Age \<55 and spontaneous menses within the past 1 year, but currently amenorrheic (e.g., spontaneous or secondary to hysterectomy), and with postmenopausal gonadotrophin levels (luteinizing hormone and follicle stimulating hormone levels >40 IU/L) or postmenopausal estradiol levels (\<5 ng/dL) or according to the definition of "postmenopausal range" for the laboratory involved.
    • Bilateral oophorectomy
    • Radiation menopause
  • Presence of (by clinical/radiological examination - according to criteria : minimum indicator lesion size : 20 mm (unless spiral CT scan in which case > 10 mm)
  • performance status of 0, 1 or 2
  • Adequate bone marrow function (WBC ≥ 3.5 x 1'000'000'000/L and ≥ 100.0 x 1'000'000'000/L) and > 10.0 g/dl
  • Adequate renal function (creatinine \< 120 µmol/L) and hepatic function ( \< 25 µmol/L, (SGOT \< 60 U/L)
  • Minimum of at least 6 months
  • Patients who are accessible for treatment and follow-up

Exclusion criteria

Exclusion Criteria:

  • Presence of non- only
  • Other concomitant anti-cancer treatment (except external radiation treatment [XRT] for symptomatic lesions if other assessable untreated lesions are present)
  • Prior treatment with aromatase inhibitors or anti-estrogens (up to one previous progestational hormone therapy regimen for recurrent disease is permitted)
  • Clear cell or papillary serous histology, uterine sarcomas, mixed Mullerian tumors (MMT) and/or adenosarcomas
  • Other concurrent malignant disease with the exception of cone-biopsied in situ carcinoma of the cervix uteri, or adequately treated basal or squamous cell carcinoma of the skin, or other curable cancers e.g. Hodgkin's disease or non-Hodgkin lymphoma (NHL), provided 5 years have elapsed from completion of therapy, and there has been no recurrence
  • Known central nervous system (CNS) metastases, bilateral diffuse lymphangiosis carcinoma of the lung (>50 % of lung involvement, or dyspnea at rest requiring supplemental oxygen therapy), evidence of metastases estimated as more than a third of the liver as defined by sonogram and/or CT scan
  • Uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or hyperthyroidism, Cushing's Syndrome, Addison's disease (treated or untreated)
  • Unstable angina and uncontrolled cardiac disease
  • Treatment with other drugs (drugs not marketed for any indication) within the past 30 days and/or the concomitant use of investigational drugs
  • A history of non-compliance to medical regimens and patients who, in the opinion of the investigator, are unlikely to cooperate fully during the study
  • Inability to swallow pills

Additional protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Letrozole

    Drug: Letrozole

Interventions

06

What researchers measure

Primary outcomes

  1. clinical response rate (partial response PR and complete response CR) according to RECIST at least once during the treatment period

    Time frame: until disease progression

Secondary outcomes

  1. Time to progression (TTP)

    Time frame: until disease progression

  2. Overall survival (OS)

    Time frame: until disease progression

07

Study locations

15 sites
  • Ebersberg, Germany
    Celle, Germany
  • Heidelberg, Germany
    Ebersberg, Germany
  • Novartis Investigative Site
    Freiburg, Germany
  • Ebersberg, Germany
    Hamburg, Germany
  • Novartis Investigative Site
    Hamburg, Germany
  • Celle, Germany
    Hannover, Germany
  • Tuebingen, Germany
    Heidelberg, Germany
  • Novartis Investigative Site
    Karlsruhe, Germany
  • Muenchen, Germany
    Kiel, Germany
  • Muenchen, Germany
    Muenchen, Germany
  • Novartis Investigative Site
    Muenchen, Germany
  • Novartis Investigative Site
    Oberaudorf, Germany
  • Novartis Investigative Site
    Rostock, Germany
  • Novartis Investigative Site
    Tuebingen, Germany
  • Hannover, Germany
    Wolfsburg, Germany
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2005 and a primary completion of May 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 15, 2005
Start
Apr 2005
Primary completionActual
May 2010
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00171808
Responsible party
Sponsor
First posted
Sep 15, 2005
Start date
Apr 2005
Primary completion
May 2010
Last update
Nov 18, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmeceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Letrozole

Start the discussion